Sylvia Adams, MD
With the prospect of phase III data that could confirm their efficacy, checkpoint inhibitors against PD-1 and PD-L1 have shown promise, both as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer (TNBC), Sylvia Adams, MD, said during a presentation at the 16th Annual International Congress on the Future of Breast Cancer East.
The presence of tumor infiltrating lymphocytes (TILs) is often associated with response to PD-1 or PD-L1. In breast cancer, PD-L1 expression is almost exclusively seen on TILs and not the tumor cells. Consequently, PD-L1 expression is highest in patients with TNBC, inflammatory breast cancer, and ductal carcinoma in situ. At present, the most promising results have been observed in the TNBC population, with early findings showing promise in the neoadjuvant space.
Active as Monotherapy
Reported findings from a few early phase studies show that the PD-1 inhibitor pembrolizumab (Keytruda) and the PD-L1 inhibitor atezolizumab (Tecentriq) have shown durable responses, with higher rates seen in the earlier settings for those with metastatic TNBC.
... to read the full story